Trial Profile
A Double-Masked Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Participants With Previous NAION
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs RPh 201 (Primary)
- Indications Optic nerve disorders
- Focus Therapeutic Use
- Acronyms NAION
- Sponsors Regenera Pharma
- 08 Oct 2020 Status changed from recruiting to discontinued.
- 09 Jul 2020 Primary endpoint added, secondary outcomes updated, planned number of patients decreased from 234 to 200, trial was phase III it is changed to phase II as a result registration tag was removed.
- 01 Jul 2020 Planned number of patients changed from 234 to 200.